Table 4 Clinical features of the study patients according to use of empiric antibiotic therapy at IMDC onset (No. of patients with IMDC = 434)
Feature | Antibiotic therapy at IMDC onset (n = 41) | No antibiotic therapy (n = 393) | p |
|---|---|---|---|
Immunosuppressive therapy for IMDC, n (%) | 41 (100.0) | 235 (59.8) | < 0.001 |
Median duration of IMDC symptoms, days (IQR) | 17 (8–32) | 8 (3–19) | 0.888 |
Hospitalization, n (%) | 41 (100) | 190 (48.3) | < 0.001 |
Median duration of hospitalization, days (IQR) | 9 (4–15) | 5 (3–8) | 0.003 |
ICU admission, n (%) | 3 (7.3) | 8 (2.0) | 0.076 |
Grade of colitis, n (%) | 0.001 | ||
 1 | 6 (14.6) | 68 (24.5) |  |
 2 | 12 (29.3) | 138 (49.6) |  |
 3 | 22 (53.7) | 62 (22.3) |  |
 4 | 1 (2.4) | 10 (3.6) |  |
Grade of diarrhea, n (%) | < 0.001 | ||
 1 | 4 (9.8) | 125 (31.8) |  |
 2 | 8 (19.5) | 112 (28.5) |  |
 3 | 24 (58.5) | 140 (35.6) |  |
 4 | 5 (12.2) | 16 (4.1) |  |
Median duration of steroid administration, days (IQR) | 39 (23–64) | 45 (23–70) | 0.496 |
Intravenous steroid administration, n (%) | 35 (85.4) | 112 (50.2) | < 0.001 |
Infliximab/vedolizumab administration, n (%) | 18 (43.9) | 65 (16.5) | < 0.001 |
Recurrence of IMDC, n (%) | 13 (31.7) | 70 (17.8) | 0.038 |
Colon perforation, n (%) | 1 (2.4) | 6 (1.5) | 0.503 |